Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 6,927 shares of the firm's stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $150.27, for a total value of $1,040,920.29. Following the sale, the insider owned 1,525,929 shares of the company's stock, valued at $229,301,350.83. The trade was a 0.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Suma Krishnan also recently made the following trade(s):
- On Thursday, July 10th, Suma Krishnan sold 6,800 shares of Krystal Biotech stock. The shares were sold at an average price of $150.28, for a total value of $1,021,904.00.
- On Wednesday, July 9th, Suma Krishnan sold 200 shares of Krystal Biotech stock. The shares were sold at an average price of $150.14, for a total value of $30,028.00.
Krystal Biotech Price Performance
Shares of KRYS stock traded down $1.57 during trading on Friday, reaching $148.17. The company had a trading volume of 267,497 shares, compared to its average volume of 287,362. The firm's 50 day simple moving average is $135.82 and its two-hundred day simple moving average is $156.26. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $219.34. The company has a market capitalization of $4.28 billion, a PE ratio of 35.62 and a beta of 0.67.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The company had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. Analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on KRYS. HC Wainwright reiterated a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a report on Tuesday, June 24th. Guggenheim reduced their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Citigroup reiterated a "neutral" rating and set a $176.00 price target (up from $155.00) on shares of Krystal Biotech in a report on Wednesday. Finally, Chardan Capital reiterated a "buy" rating and set a $219.00 price target on shares of Krystal Biotech in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech currently has an average rating of "Buy" and an average target price of $213.75.
Get Our Latest Stock Report on KRYS
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. FMR LLC increased its position in Krystal Biotech by 0.5% in the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after buying an additional 21,133 shares during the period. Vanguard Group Inc. increased its position in Krystal Biotech by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after buying an additional 28,707 shares during the period. Avoro Capital Advisors LLC increased its position in Krystal Biotech by 0.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after buying an additional 6,600 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Krystal Biotech by 173.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after buying an additional 365,304 shares during the period. Finally, Hood River Capital Management LLC increased its position in Krystal Biotech by 2.1% in the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock worth $80,324,000 after buying an additional 10,622 shares during the period. 86.29% of the stock is owned by institutional investors.
Krystal Biotech Company Profile
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
See Also
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
